In the past quarter of a century, our understanding of the metabolism and mechanism of action of vitamin D has been elucidated. During this period, many metabolites of vitamin D have been identified and a small proportion of these assayed in blood. The ability to assay these vitamin D metabolites has led to a better appreciation of the pathological role that altered vitamin D metabolism plays in the development of diseases of calcium homeostasis. However, for many physicians it is not clear which vitamin D metabolites should be quantitated and what the information gained tells us. Of the four major circulating vitamin D metabolites in blood, only two, namely 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D [1,25(OH) 2 D], have warranted measurement. Of these, the need for assessing serum 1,25(OH) 2 D is actually quite limited and should therefore not be considered as part of the standard vitamin D testing regimen. 25OHD, on the other hand, provides us with the single best assessment of vitamin D nutritional status and should be the only vitamin D assay typically ordered for this reason.
Introduction
Although more than 40 di¡erent metabolites of vitamin D have been identi¢ed to date, 1 the parent sterol vitamin D and its metabolites 25-hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D [1,25(OH) 2 D] have received the greatest attention with respect to their role in calcium and phosphate homeostasis. The development of sensitive and speci¢c assays for these vitamin D metabolites has been an invaluable research tool in de¢ning vitamin D action and many of the diseases resulting from altered vitamin D metabolism. The application of these assays in the clinical biochemistry laboratory has proceeded much more slowly. This has been due in large part to the inherent problems associated with these assays and the detection of the vitamin D metabolites that circulate in the nano-to micromolar concentration range. As will be discussed, the clinical utility of quantitating vitamin D in serum for diagnostic purposes is rather limited. This review will consider what information may be obtained from measurement of vitamin D and its principal metabolites 25OHD and 1,25(OH) 2 D and what methods are available for performing these assays. lipophilic nature of vitamin D and the consequent di⁄culty of extraction from aqueous media utilizing solid-phase extraction techniques such as C 18 silica Sep-Pak cartridges that result in low yield of vitamin D from serum or plasma. 4 Instead, vitamin D must be extracted using liquid-liquid organic extraction techniques. Early assays employed organic solvent extraction of the specimen, usually with chloroformmethanol (1:2, v/v), 5, 6 followed by phase separation with chloroform and water. 7 The lower chloroform phase contains 85-95% of the vitamin D and must be taken to dryness before puri¢cation can be performed. More recently, methanol and hexane have been used for sample extraction. 8 However, this type of organic solvent extraction also removes a large amount of the total lipids from the plasma sample, necessitating additional puri¢cation with open cartridge silica chromatography prior to assay. In addition, exceptionally large volumes of serum are required in order to have su⁄cient puri¢ed material for assay. Without this subsequent puri¢cation, values obtained for serum vitamin D concentration using competitive protein binding (CPB) assays are about 10-15-fold higher than values reported by others using highperformance liquid chromatography (HPLC) and ultraviolet (UV) detection. Although CPB still represents a sensitive method for assaying 25OHD (see below), most assays for vitamin D utilize extensive puri¢cation followed by UV detection on HPLC. 8 This method also has the added advantage of being able to quantitate both cholecalciferol (vitamin D 2 ) and ergocalciferol (vitamin D 3 ) in a single specimen. This could prove useful if one wishes to assess the contribution of a pharmacological or dietary source of vitamin D 2 to a patient's overall vitamin D status.
The major steps of the HPLC vitamin D assay include a methanol-hexane extraction of 0.5-1.0 mL of serum or plasma after the addition of 1000 counts/ min of 3 H-labelled vitamin D 3 to monitor recovery of the endogenous compound through the ensuing extraction and chromatographic procedures. The lipid residue is thenapplied to a small silicic acid columnand the vitamin D fraction eluted with 0.2% (v/v) isopropanol in methylene chloride. This step e¡ectively separates vitamin D from the more polar metabolites, 25OHD and 1,25(OH) 2 D. The vitamin D fraction is then applied to a straight-phase HPLC system and the vitamin D fraction eluted with hexane-methylene chloride-isopropanol (49.5:49.5:0.5, v/v). Final resolution of vitamin D 2 and D 3 is accomplished via reversed-phase HPLC on a non-end-capped octadecylsilane column using acetonitrile-methylene chloride (65: 35 , v/v) as mobile phase. After elution, the peak height at 265 nm is quantitated and compared to that obtained with authentic standards. The vitamin D peaks are collected, taken to dryness, and counted in a liquid scintillation system to quantitate ¢nal recovery. The value obtained from UV detection is then corrected for the percentage recovery.
Vitamin D: assay performance
Currently, there are no commercially available parent vitamin D assays. Thus, irrespective of the type of puri¢cation procedure and assay methodology to be employed, it is important that the concentration of the standards be accurately prepared. The simplest approach to this is to dissolve a su⁄cient amount of vitamin D in ethanol and measure the optical density via HPLC at 265 nm and to calculate the concentration using the extinction coe⁄cient of 18 300 L/mol/cm. Moreover, if vitamin D is to be quantitated via CPB, caution should be exercised in the choice of species from which the serum vitamin D binding protein is to be obtained. This is because not all species have equal a⁄nity for both vitamin D 2 and D 3 . For example, rat, cow and human plasma vitamin D binding protein demonstrate a 5-10-fold reduced a⁄nity for vitamin D 2 . 9 If serum vitamin D 2 determinations are needed, then D 2 must be separated from D 3 and the appropriate standards used in each assay. If one of these vitamin D binding proteins were to be used in a vitamin D assay that did not separate the two forms of vitamin D, values might be falsely lowered due to the reduced a⁄nity of the binding protein for vitamin D 2 . Despite this potential problem, it is unlikely that measurement of both vitamin D 2 and D 3 would be required in a clinical setting. In addition, it has been suggested that the conversion of vitamin D 2 to 25OHD 2 in man is not as e⁄cient as that for the D 3 form of the vitamin, 10 further limiting the clinical usefulness of this measurement. There is little clinical utility in de¢ning an individual's vitamin D status from an examination of the circulating vitamin D concentration, be it D 3 or D 2 .
25-Hydroxyvitamin D
Unlike parent vitamin D, quantitation of serum 25OHD provides a clinically useful assessment of an individual's vitamin D status for several reasons. First, the serum half-life of 25OHD is approximately 3 weeks. 12, 13 This rather long serum half-life thus provides an indication of vitamin D stores obtained from both UV radiation and dietary intake over long periods. Initially it was believed that measuring both 25-hydroxycholecalciferol (25OHD 3 ) and 25hydroxyergocalciferol (25OHD 2 ) (see Fig. 1 ) could provide information about sunlight-induced versus dietary sources of vitamin D. 14 This is no longer true since forti¢cation of milk with vitamin D and preparation of multivitamins is now performed with both forms of the vitamin, so separate measurement of the metabolites is of little value. Second, it is now clear that liver production of 25OHD is not signi¢cantly regulated and that 25OHD production is primarily dependent on substrate concentration. 15, 16 There is no better demonstration of this substrate dependability than in the well-documented seasonal variation of serum 25OHD in ambulatory normal subjects. 17 For these reasons, measurement of serum 25OHD provides the best estimate of a patient's vitamin D status. It is also the assay that has received the greatest attention with respect to establishment in a clinical biochemistry laboratory. Two assays for the measurement of 25OHD were introduced in 1971. 5, 18 One is identical to the assay for vitamin D discussed above (organic solvent extraction followed by silicic acid chromatography to separate vitamin D from 25OHD 5 ). The partially puri¢ed 25OHD fraction was then quantitated via CPB assay using vitamin D-de¢cient rat serum as the source of the vitamin D binding protein.
The assay reported the normal circulating concentration range of 25OHD to be 18-36 mg/L (43-86 nmol/ L), which is remarkably similar to that observed recently by other methodologies. However, this assay required a 10-day incubation, which made the assay impractical for routine clinical use. At the same time, a variant of this procedure was also reported. 18 This CPB assay also utilized silicic acid chromatography to separate vitamin D from 25OHD. However, the method di¡ered in that samples were extracted with ether, eliminating the cumbersome chloroform-methanol extraction and subsequent phase separation. Second, incubation times were reduced from 10 days to 1h, making this assay practical for application in most clinical laboratories. There have been several variations on this basic CPB assay that incorporate di¡erent extraction procedures or alternative puri¢cation schemes but with no real improvement in assay performance. A commercially available CPB assay for 25OHD is currently available from Immunodiagnostik (Bensheim, Germany).
In 1977, the ¢rst useful direct UV detection assay for 25OHD was reported. 19 25OHD circulates at micromolar concentrations, thus permitting direct quantitation via UV detection. This assay utilized a cumbersome chloroform-methanol solvent extraction of serum, a chromatographic procedure on Sephadex LH-20 to remove interfering lipids and vitamin D, and UV detection following HPLC. This method has the advantage of being able to separate 25OHD 2 from 25OHD 3 and thus permits their individual quantitation. It requires expertise and equipment that is usually only available in research laboratories. However, for laboratories equipped with HPLC instrumentation, an HPLC application for the determination of 25OHD 3 is commercially available from Immunodiagnostik. This method employs an initial acetonitrile extraction of the serum sample and provided calibrators. The protein-free supernatant is then applied to a C 18 Sep-Pak cartridge for solid-phase extraction and, after washing, the 25OHD fraction eluted with the provided elution bu¡er. The dried eluate is then applied to a straight-phase HPLC silica column. Concentration is determined from peak area after calibration with provided standards. Based on the manufacturer's product insert, it is not clear if the chromatographic system can fully resolve 25OHD 2 from 25OHD 3 .
In order for this assay to receive more widespread acceptance in the clinical biochemistry laboratory, it was necessary to simplify the extraction procedure and eliminate the chromatographic puri¢cation steps. These limitations were surmounted with the introduction of the ¢rst valid radioimmunoassay (RIA) for 25OHD in 1985. 20 This assay did not require sample prepuri¢cation prior to assay. Furthermore, its overall sensitivity was greatly enhanced with the use of 125 Ilabelled tracer in place of [ 3 H]25OHD. This assay also does not require addition of tracer 25OHD to serum specimens for determination of sample yield following puri¢cation since the standards for this RIA are serum-based and are treated in the same manner as patients' samples or unknown specimens. In this assay, 50 mL of serum or plasma is extracted with 500 mL of acetonitrile and the supernatant taken for assay without further puri¢cation. Because of the overall simplicity of this assay and its strong correlation with values obtained from HPLC analysis, this assay has been approved by the Food and Drug Administration for clinical use in the USA (DiaSorin, Stillwater MN, USA). It recognizes both 25OHD 2 and 25OHD 3 with equal a⁄nity as well as a number of other circulating vitamin D metabolites such as 24,25dihydroxyvitamin D, 25,26-dihydroxyvitamin D and 25OHD 3 -26,23-lactone. However, since these latter metabolites only account for about 6% of the overall circulating concentration of vitamin D and its metabolites, their contribution can be ignored under this assay format. Recently, a second commercially available RIA for 25OHD has become available (IDS, Boldon, UK). This RIA is performed in much the same way as the previous assay except that there is a twostep extraction procedure that is applied to all serum samples, calibrators and controls. The remainder of the procedure is the same as that described above. Correlation between the two RIAs is very good (r 2 ¼ 0.92, n ¼ 68; manufacturer's product information). Two additional enzyme-linked immunosorbent assays (ELISAs) as well as a fully automated chemiluminescence assay for the measurement of 25OHD in serum or plasma have also become available recently. The chemiluminescence assay (Nichols Diagnostic, San Juan Capistrano CA, USA) is rapid, averaging 75 min to the ¢rst result at a rate of 75 tests/h. Sample volume requirement is a mere 20 mL, but the detection limit [de¢ned as the concentration at which interassay coe⁄cient of variation (CV) is 20%] is rather high at 7 mg/L (18 nmol/L). 21 The assay is equally speci¢c for both 25OHD 2 and 25OHD 3 . However, the need for expensive instrumentation to perform the assay under this format has limited its widespread acceptance. Of the two remaining assays, one ELISA assay (IDS) utilizes biotin-labelled 25OHD which is added to the calibrators, controls and 25 mL of nonextracted serum or plasma samples. The diluted samples are then incubated for 2 h in microtitre wells that are coated with a sheep antibody to 25OHD. After aspiration and washing of the wells, colour development is accomplished via incubation with horseradish-peroxidase-labelled avidin and 3,3 0 ,5,5 0tetramethylbenzidine (TMB) as the chromogenic substrate. The absorbances of the stopped reaction mixtures are read in a microtitre plate reader where colour intensity is inversely proportional to the concentration of 25OHD. Compared to 25OHD 3 , this antibody has 75% cross-reactivity with 25OHD 2 . Although the antibody is reported to have100% crossreactivity with 24,25-dihydroxyvitamin D 3 and possibly other dihydroxylated vitamin D metabolites, the low contribution of these metabolites to the overall concentration in serum (56%) minimizes any concern over possible interference in the ELISA. The second ELISA assay (Immunodiagnostik) takes advantage of the strong a⁄nity of 25OHD for the serum vitamin D binding protein. It employs an antibody directed against the serum vitamin D binding protein that has been coated onto microtitre wells. A single extraction procedure is applied to all samples (50 mL), calibrators and controls. After extraction, 25 mL of the supernatant and an aliquot of the vitamin D binding protein are added to each well of a microtitre plate that is coated with the antibody. Following a 3 h incubation, the wells are washed, then a conjugate of peroxidase is added and incubated for 1h. After washing, colour development is initiated with the addition of TMB as substrate. As might be expected with an antibody to the vitamin D binding protein, this assay also reports 100% cross-reactivity with 24,25(OH) 2 D in this assay format. However, due to the low circulating concentration of 24,25(OH) 2 D in blood, overall contribution to the calculated 25OHD concentration would be negligible. the performance characteristics of each of these assays for 25OHD.
1,25-Dihydroxyvitamin D
The physiologically active form of vitamin D is 1,25(OH) 2 D, produced from 25OHD in the kidney (see Fig. 1 ). Unlike the conversion of vitamin D to 25OHD, the enzymatic conversion of 25OHD to 1,25(OH) 2 D is tightly regulated. This fact, and the relatively short serum half-life of1,25(OH) 2 D (of the order of 4-6 h), 22 limit the clinical utility of serum 1,25(OH) 2 D measurements. Development of a convenient and accurate assay for 1,25(OH) 2 D was initially hampered by the low circulating concentration that precludes UV quantitation, strong lipophilicity, lability and interference from its precursor, 25OHD, that circulates at concentrations at least 1000-fold higher than that of 1,25(OH) 2 D. The ¢rst assay for 1,25(OH) 2 D was reported in 1974. 23 This was a radioreceptor assay and was extremely time consuming to perform. Limitations to this assay were the large sample volume (20 mL of serum), methanol-chloroform solvent extraction and separation, three successive chromatographic puri¢cations, and the need to prepare fresh intestinal vitamin D receptor from rachitic chickens each time the assay was performed. Nevertheless this early assay was extremely useful in the research arena for delineating vitamin D metabolism in certain metabolic diseases of calcium homeostasis. By 1976, the sample requirement had been reduced to 5 mL and HPLC had been incorporated into the puri¢cation scheme in place of Celite column chromatography. 24 Ann Clin Biochem 2004; 41: 272-281 However, sample extraction was still accomplished via the cumbersome methanol-chloroform methodology, and a sample prepuri¢cation on Sephadex LH-20 was still necessary. In 1978, the ¢rst RIA for 1,25(OH) 2 D was introduced. Although this assay circumvented the need to prepare the chick intestinal receptor protein, the antibody was relatively non-speci¢c and sample prepuri¢cation was still required. 25 These limitations with the assay for 1,25(OH) 2 D precluded it from being established in clinical biochemistry laboratories. The most signi¢cant advance in the assay of 1,25(OH) 2 D came in 1984 with the introduction of solid-phase extraction of the metabolite from serum and the incorporation of silica cartridge puri¢cation of 1,25(OH) 2 D. 26 In addition, the vitamin D receptor protein was obtained from calf thymus glands that yielded a preparation that was quite stable for many months if kept frozen. This eliminated the need for daily preparation of the vitamin D receptor from chick intestine, a major impediment to the use of this assay in laboratories. Lastly, the serum volume requirement was reduced to 1mL, permitting use in paediatric patients. All of these improvements in the 1,25(OH) 2 D radioreceptor assay led to the implementation of this assay in several reference laboratories. However, the need to prepare vitamin D receptor still represented a signi¢cant shortcoming to the widespread application. Furthermore, iodine-labelled 1,25(OH) 2 D was not available for use as the tracer, limiting establishment of this assay. Despite these limitations, a commercially available radioreceptor assay for 1,25(OH) 2 D 3 is currently available (Immunodiagnostik).
In 1996, the ¢rst clinically useful RIA for 1,25(OH) 2 D was reported. 27 This RIA (DiaSorin, Stillwater MN, USA), like that for 25OHD, incorporated 125 I-labelled 1,25(OH) 2 D and provided calibrators in an equivalent serum matrix, eliminating the need for determining individual sample recoveries. It was shown to correlate well with the radioreceptor assay (r 2 ¼ 0.961) and to provide 1,25(OH) 2 D values that were appropriate for the clinical condition being assessed. Both the analytical and clinical validation of this assay have recently been reported. 28 A second commercially available RIA (IDS, Boldon, UK) for 1,25(OH) 2 D has also been described. 29 This RIA makes use of an immunoextraction procedure to separate 1,25(OH) 2 D from delipidated serum samples. The extracted 1,25(OH) 2 D is then eluted from the immunocapsule, taken to dryness, and added directly to the immunoassay after reconstitution. Comparison with a commercial radioreceptor assay and an inhouse RIA gave good correlations (r 2 ¼ 0.96 and 0.90, respectively). One study, however, has suggested that 1,25(OH) 2 D serum concentrations determined with the IDS assay may overestimate the true concentration due to interference from other 1a-hydroxylated vitamin D metabolites that are also captured by the immunoextraction procedure. 30, 31 These metabolites include 1,25(OH) 2 D 3 -26,23-lactone, 1,24,25(OH) 3 D 3 and 1,25,26(OH) 3 D 3 and can account for up to 30% of the measured circulating 1,25(OH) 2 D concentration. Without some type of chromatographic separation to remove these other 1a-hydroxylated vitamin D metabolites, non-speci¢c interference in this type of assay remains a potential problem. It is also important to point out that antibody speci¢city in the currently available RIAs for 1,25(OH) 2 D is relatively poor, thus necessitating some type of sample prepuri¢cation prior to assay. Although HPLC would be ideal in this regard, it is not easily incorporated into many clinical biochemistry laboratories due to its cost and slow sample turnaround time. The DiaSorin assay addresses this issue by including a 30-min pretreatment of the serum acetonitrile extracts with sodium periodate. This step e¡ectively converts all of the 24,25(OH) 2 D and 25,26-(OH) 2 D to their respective aldehyde and ketone forms, which are easily removed by a subsequent chromatographic step. This chromatographic step also serves to remove other 1a-hydroxylated metabolites in serum that show appreciable crossreactivity with the antibody.
In addition to these RIAs for 1,25(OH) 2 D, an ELISA format has also been introduced (Immunodiagnostik). Samples, calibrators and controls are all subjected to a two-column extraction procedure to extract the 1,25(OH) 2 D from the sample and to separate it from other interfering vitamin D metabolites. The puri¢ed samples, calibrators and controls are then pre-incubated with a primary antibody to 1,25(OH) 2 D for 1h before transfer to microtitre wells that are coated with1,25(OH) 2 D. During the ensuing overnight incubation, an equilibrium is attained between the 1,25(OH) 2 D in the samples, the 1,25(OH) 2 D coated to the wells and the primary antibody. Thus, with increasing1,25(OH) 2 D concentration in the specimen, less antibody is available for binding to the1,25(OH) 2 D coated on the wells. After an overnight incubation, the wells are washed and a secondary peroxidase-labelled antibody added using TMB as the enzyme substrate. The intensity of the colour development is indirectly proportional to the concentration of1,25(OH) 2 D in the sample. This assay has demonstrated good correlation with a 3 H-radioreceptor assay (r 2 ¼ 0.96). There are limited data regarding this assay's performance with clinical specimens from patients with renal failure, hypoparathyroidism and hyperparathyroidism. A second ELISA for 1,25(OH) 2 D is expected to be available soon from IDS. It will have a format similar to the IDS ELISA assay for 25OHD. Table 2 summarizes some of the performance characteristics of each of these assays for1,25(OH) 2 D.
Summary and recommendations
What metabolite should be measured?
It has been 80 years since the initial description of a semi-quantitative bioassay for vitamin D anti-rachitic activity. 32 During that time, our understanding of vitamin D metabolism and action has disclosed an elaborate mechanism for regulation of calcium homeostasis in humans. This knowledge has been gained, in large part, from advances in the methodologies for quantitating vitamin D and its metabolites. While these assays have been extensively utilized for research purposes, it has only been in the last 10 years that their increasing use in the clinical laboratory has occurred. Today, there is no compelling reason for quantitation of circulating vitamin D. It is a poor indicator of vitamin D nutritional status due to its short circulating half-life and sensitivity to recent sun exposure and dietary vitamin D intake. Similarly, assay of 1,25(OH) 2 D, the physiologically active form of vitamin D, also has limited usefulness in the clinical setting. While it is diagnostic for several clinical conditions, including pseudovitamin D de¢ciency rickets, hereditary 1,25(OH) 2 D-resistant rickets and hypercalcaemia resulting fromvarious granulomatous disorders, it is simply a con¢rmatory test in all other disorders involving the vitamin D endocrine system. Because its production is tightly regulated, circulating 1,25(OH) 2 D measurement provides limited information with respect to a patient's nutritional vitamin D status and this should therefore not be used for this assessment. It is recommended thatassayof serum1,25(OH) 2 D be left to regional or large reference laboratories. On the other hand, vitamin D nutritional status is clearly represented by the circulating concentration of 25OHD. Therefore, the most clinically useful assay is for 25OHD, and this should be the principal assay established in the clinical laboratory setting.
What assay platform should be utilized?
Deciding which vitamin D assay format to utilize is di⁄cult. As pointed out, assays for 25OHD and for 1,25(OH) 2 D are available in several platforms. Establishing an 'in-house' assay may be more cost-e¡ective than purchasing commercially available assays, providing that there is appropriate equipment and expertise.Workload should also be considered in light of the commercial reagents' shelf-life and cost. For laboratories with a larger testing volume, one of the commercially available RIA or ELISA procedures may be suitable. Currently, there are seven commercially available assays for 25OHD. Choosing among these various assays can be di⁄cult as there have been no head-to-head comparisons. The exception has been for the Nichols chemiluminescence assay and the DiaSorin RIA which have been compared against HPLC detection, considered by most to be the gold standard. That study disclosed discordance for serum 25OHD values between the two assays and, compared with HPLC, both assays underestimated 25OHD concentration. 33 This ¢nding further emphasizes the need to establish assay-speci¢c clinical decision limits in each clinical biochemistry laboratory. For serum 1,25(OH) 2 D, establishing an 'in-house' procedure should be avoided unless sample numbers are exceptionally high and cost concerns become an issue. The DiaSorin RIA or the Immunodiagnostik ELISA would appear to be good choices for commercially available 1,25(OH) 2 D assays. While the IDS RIA o¡ers a novel immunoextraction step that eliminates the need for extensive chromatographic puri¢cation, each clinical biochemistry laboratory must determine if there is a signi¢cant contribution to the measured value by other 1a-hydroxylated metabolites. Quality control concerns for each of the assays must also be considered. While most of the commercially available assay kits (RIA/ELISA) will contain the manufacturer's own quality control material, there is little else available from commercial reference sources. A suitable serum control for 25OHD is available from Bio-Rad Laboratories (Hercules CA, USA), but there is no commercially available control serum for 1,25(OH) 2 D. Two external quality assessment schemes (EQAS) are available in Europe for these vitamin D metabolites. There is an independent EQAS for 25OHD in the UK 11 and a similar EQAS for 25OHD and 1,25(OH) 2 D that is provided by Labquality (www.labquality.¢), an international organizer of EQAS. There is no commercially available assayed quality control serum for 1,25(OH) 2 D at present. Additionally, it should be emphasized that it is critically important for each laboratory to establish their normative data for the vitamin D metabolites. Although there is fairly good agreement on the normal range for serum 1,25(OH) 2 D between the various assays and laboratories performing them, there is much greater variability with serum 25OHD. This is due, in part, to the time of year that samples are taken, since values tend to be highest in August and lowest in February. While it is possible to determine the normal range in an adequate number of individuals during just1month, it is necessary to specify what month this normal range was established so that the patient's value can be interpreted in light of the known seasonal variability.
Another confounding factor in evaluating vitamin D assay performance is the potential interfering e¡ect of some new vitamin D analogues used clinically. The three analogues that have received most attention are calcipotriol, 22-oxacalcitriol and paricalcitol. All three of these compounds have an A-ring structure identical to that of 1,25(OH) 2 D 3 but various modi¢cations of the side-chain structure. Although all of these compounds interact with the vitamin D receptor, the a⁄nities have been reported to be quite variable depending on the manner in which the assay is performed. 34 This would imply that such compounds when administered in pharmacological amounts could interfere with the assay for 1,25(OH) 2 D if performed as a radioreceptor assay. It is less likely that these analogues or their metabolites would interfere with the assay of 25OHD since the latter circulates at about 1000-fold higher concentration than that of the analogues. At present, it is not known to what extent these compounds are metabolized and whether the metabolites have the capacity to bind to the vitamin D receptor or to be recognized by the antibodies utilized in the various RIAs. Since most of these metabolites are cleared rather rapidly following administration, it would be wise to obtain the blood for vitamin D assay 24 h after the last dose of these vitamin D analogues in order to prevent possible interference with the determination of 1,25(OH) 2 D.
Lastly, most assays of vitamin D metabolites can be performed with either serum or plasma, which should be stored frozen at 7208C until assay. Early studies concerned with 25OHD stability in serum determined that this metabolite was stable in frozen serum for periods of up to 2 years. 35, 36 A subsequent study of both 25OHD and 1,25(OH) 2 D stability in blood disclosed these metabolites to be stable in uncentrifuged blood for as long as 72 h at 248C. 37 In addition, exposure to UV light and repeated (up to 11 times) freezing and thawing of a serum pool was without apparent e¡ect on analyte stability.We have also found samples to be stable for up to 1 year when stored at 7208C with no loss of vitamin D metabolite when assayed (unpublished observations). Thus, unlike the situation with puri¢ed vitamin D metabolites, vitamin D compounds present in human serum and plasma are protected from degradation by heat or light, possibly by the presence of the vitamin D binding protein.
In summary, there is no real need to establish an assay for serum 1,25(OH) 2 D in most clinical biochemistry laboratories. On the other hand, assessment of serum 25OHD provides the best indicator of a patient's overall vitamin D repletion and should be the assay of choice for any laboratory contemplating assessment of vitamin D status. There are currently numerous commercially available assays for 25OHD, thus eliminating the need for establishing an in-house assay. The choice as to which assay or methodology to employ for measuring serum 25OHD will depend in large part on the available equipment and expertise of each laboratory. In addition, the commercial availability of a control serum as well as two di¡erent external quality assessment schemes for 25OHD lend further endorsement for assay of this vitamin D metabolite. Although the vitamin D metabolites are known to be quite stable in frozen serum, it is imperative that each laboratory establishes its own assay-speci¢c clinical decision limits. 
